Healthcare · Pharma (Chronic Care - Diabetes & Cardiology)
Awaiting a verified source quote. No third-party quote is on record for this company yet, so there is no indicative price to show — and we would rather leave it blank than print a number we cannot stand behind. Our team can confirm the current dealable level directly.
Indicative private-market reference — not an exchange quote. Not investment advice.
Two separate things, deliberately shown side by side: a sourced private-market price reference, and the depth of research that actually stands behind this company today.
No third-party quote has been sourced for this company yet, so there is no market reference to show. Ask us to check the current level and we will come back with what the market is actually doing.
Real, dated third-party observations only — plotted where they exist, never interpolated, extended or carried forward. This is a record of private-market sightings, not a live exchange chart.
Price history not available. No dated third-party quotes have been sourced for this company yet.
Assembled only from records that exist for this company. Anything not disclosed says so.
USV is an India-based pharmaceutical company focused on chronic-care therapy areas, particularly diabetes and cardiovascular disease, manufacturing formulations and active pharmaceutical ingredients across seven plants in India and exporting to more than 65 countries. Founded in Mumbai in 1961, the company is privately held and chaired by Leena Gandhi Tewari, with the Gandhi Tewari family as controlling shareholders.
Source: USV Private Limited (official) / ToflerCompetes in the diabetes-care segment with Sun Pharma, Abbott India and multinational players such as Novo Nordisk.
Source: Not attributedControlled by the Gandhi Tewari family, with Leena Gandhi Tewari as Chairperson
Promoters & principal holders: Leena Gandhi Tewari
Unlisted, family-controlled
We would rather say that plainly than publish a page that looks finished.
No financials, no implied valuation and no peer comparison have been researched for this company yet.
No Prospera Private Market Score and no Prospera view exist. Being in our universe is not a recommendation, and we will not manufacture one to fill this space.
What you can rely on above is what has actually been verified: the company's identity and business facts, any sourced price observations on record, and any risks that have been documented. If you want us to prioritise deeper work here, ask — that is genuinely how the queue gets set.
Documented, per-company risks — grouped by the categories the research itself recorded. There is no risk score here, because we do not compute one.
No company-specific risks have been researched and recorded for this company yet. That is an absence of research, not a clean bill of health — the standing risks of the asset class above still apply.
Dated, sourced events only — recorded as they were reported, in reverse order of significance to a private-market holder.
No corporate events have been documented for this company yet.
Every figure on this page comes from one of the records below. Where a source published a link, it is here.
| Field | Source | As of |
|---|---|---|
| Business Description | USV Private Limited (official) / Tofler | Not disclosed |
| Competitive Position | Not attributed | Not disclosed |
Every option below opens a conversation with a person at Prospera. Nothing here places, reserves or executes an order.
We will come back with the current dealable level, the available lot size and what the process actually involves. Indicative prices shown on this page are private-market references, not executable quotes.